Edition:
United Kingdom

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

30.43USD
17 Oct 2018
Change (% chg)

$-0.10 (-0.33%)
Prev Close
$30.53
Open
$30.49
Day's High
$32.01
Day's Low
$30.34
Volume
101,034
Avg. Vol
348,841
52-wk High
$85.19
52-wk Low
$26.23

Chart for

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $4,124.93
Shares Outstanding(Mil.): 48.88
Dividend: --
Yield (%): --

Financials

  CLVS.OQ Industry Sector
P/E (TTM): -- 85.92 33.73
EPS (TTM): -8.75 -- --
ROI: -72.20 0.63 14.31
ROE: -162.18 1.68 16.04

Clovis Oncology, execs to pay $20 million to settle SEC charges

WASHINGTON U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

18 Sep 2018

Clovis Oncology, execs to pay $20 million to settle SEC charges

WASHINGTON, Sept 18 U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

18 Sep 2018

BRIEF-Clovis Oncology Reports Q1 Loss Per Share $1.54

* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS

08 May 2018

BRIEF-Clovis Oncology CEO Patrick Mahaffy's 2017 Total Compensation Was $8.7 Million

* CLOVIS ONCOLOGY INC SAYS CEO PATRICK MAHAFFY'S 2017 TOTAL COMPENSATION WAS $8.7 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KnbE4y) Further company coverage:

27 Apr 2018

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥10,530 +70.00
Pfizer Inc. (PFE.N) $44.58 +0.65
AstraZeneca plc (AZN.L) 5,860.00 +97.00
BioMarin Pharmaceutical Inc. (BMRN.OQ) $105.68 -0.33
TESARO Inc (TSRO.OQ) $43.58 +0.18
AbbVie Inc (ABBV.N) $91.64 -0.27
Novartis AG (NOVN.S) CHF84.28 +0.20
Johnson & Johnson (JNJ.N) $139.12 +2.56
Eli Lilly And Co (LLY.N) $112.43 +1.40
GlaxoSmithKline plc (GSK.L) 1,494.40 +8.40

Earnings vs. Estimates